VistaGen Therapeutics Inc (VTGN)

Name: VistaGen Therapeutics Inc Financial Statements
Creator: Quarter Results

Healthcare | Biotechnology

Latest reporting period: 2026-03-31

Latest Quarter

2026-03-31

Revenue

$465K

Net Income

-$16.3M

Operating Margin

-3,595.1%

Free Cash Flow

-$66.4M

Debt / Assets

16.5%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for VistaGen Therapeutics Inc (VTGN).
Income Statement (Quarterly)	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Revenue	465,000	303,000	258,000	244,000
Cost of Revenue	0	189,000	0	169,000
Gross Profit	465,000	114,000	258,000	75,000
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	4,122,000	5,491,000	4,396,000	4,370,000
Operating Expenses	17,182,000	19,660,000	20,311,000	15,879,000
Operating Income	-16,717,000	-19,546,000	-20,053,000	-15,804,000
Interest Expense	0	0	0	0
Income Before Tax	-16,267,000	-18,899,000	-19,417,000	-15,095,000
Income Tax Expense	7,000	0	0	0
Net Income	-16,274,000	-18,899,000	-19,417,000	-15,095,000
Per Share
EPS	-0.41	-0.45	-0.54	-0.47
EPS Diluted	0.00	0.00	0.00	0.00

Income statement annual history for VistaGen Therapeutics Inc (VTGN).
Income Statement (Annual)	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Revenue	1,269,000	486,000	1,064,000	-227,000	1,108,900
Cost of Revenue	0	0	0	0	815,200
Gross Profit	1,269,000	486,000	1,064,000	-227,000	293,700
Operating Expenses
R&D Expenses	0	0	0	0	0
SG&A Expenses	18,421,000	17,084,000	14,063,000	14,664,000	13,248,000
Operating Expenses	73,395,000	56,459,000	34,085,000	59,041,000	48,655,800
Operating Income	-72,126,000	-55,973,000	-33,021,000	-59,268,000	-47,778,900
Interest Expense	0	0	0	23,000	232,000
Income Before Tax	-69,678,000	-51,411,000	-29,358,000	-59,242,000	-47,759,000
Income Tax Expense	7,000	7,000	4,000	6,000	3,400
Net Income	-69,685,000	-51,418,000	-29,362,000	-59,248,000	-47,762,400
Per Share
EPS	-1.83	-1.67	-1.52	-8.51	-7.24
EPS Diluted	0.00	0.00	0.00	0.00	0.00

Balance sheet quarterly history for VistaGen Therapeutics Inc (VTGN).
Balance Sheet (Quarterly)	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Assets
Cash and Cash Equivalents	67,131,000	119,166,000	16,637,600	68,135,300
Short Term Investments	13,351,000	0	0	0
Net Receivables	0	0	802,700	337,900
Inventory	0	0	-735,600	2,453,000
Total Current Assets	82,076,000	120,672,000	17,507,400	70,998,000
Property Plant Equipment	1,811,000	2,255,000	2,767,600	3,076,300
Goodwill and Intangibles	0	0	0	0
Total Assets	84,341,000	123,653,000	21,089,200	74,643,400
Liabilities
Account Payables	653,000	1,547,000	2,473,100	2,758,600
Short Term Debt	561,000	1,100,000	592,600	433,300
Total Current Liabilities	12,612,000	5,123,000	4,567,400	5,765,100
Long Term Debt	948,000	1,570,000	2,127,200	2,605,400
Total Liabilities	13,951,000	9,367,000	9,009,200	9,928,100
Shareholders Equity
Retained Earnings	-407,632,000	-356,214,000	-326,851,700	-267,604,000
Total Shareholders Equity	70,390,000	114,286,000	12,080,000	64,715,300

Balance sheet annual history for VistaGen Therapeutics Inc (VTGN).
Balance Sheet (Annual)	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31
Assets
Cash and Cash Equivalents	67,131,000	119,166,000	16,637,600	68,135,300	103,108,300
Short Term Investments	13,351,000	0	0	0	0
Net Receivables	0	0	802,700	337,900	40,600
Inventory	0	0	-735,600	2,453,000	0
Total Current Assets	82,076,000	120,672,000	17,507,400	70,998,000	104,117,500
Property Plant Equipment	1,811,000	2,255,000	2,767,600	3,076,300	3,587,000
Goodwill and Intangibles	0	0	0	0	0
Total Assets	84,341,000	123,653,000	21,089,200	74,643,400	108,281,300
Liabilities
Account Payables	653,000	1,547,000	2,473,100	2,758,600	838,300
Short Term Debt	561,000	1,100,000	592,600	433,300	367,800
Total Current Liabilities	12,612,000	5,123,000	4,567,400	5,765,100	4,189,000
Long Term Debt	948,000	1,570,000	2,127,200	2,605,400	3,350,800
Total Liabilities	13,951,000	9,367,000	9,009,200	9,928,100	16,302,800
Shareholders Equity
Retained Earnings	-407,632,000	-356,214,000	-326,851,700	-267,604,000	-219,841,600
Total Shareholders Equity	70,390,000	114,286,000	12,080,000	64,715,300	91,978,500

Cash flow quarterly history for VistaGen Therapeutics Inc (VTGN).
Cash Flow Statement (Quarterly)	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Operating Activities
Net Income	-69,685,000	-51,418,000	-29,362,000	-59,247,700
Depreciation & Amortization	733,000	635,000	568,000	509,800
Stock Based Compensation	3,997,000	4,315,000	2,182,000	3,336,000
Change in Working Capital	-938,000	4,760,000	793,000	2,028,200
Operating Cash Flow	-66,436,000	-42,097,000	-25,813,000	-49,715,100
Investing Activities
Capital Expenditure	-151,000	-191,000	-61,000	-212,000
Investments	-151,000	-191,000	-61,000	-212,000
Investing Cash Flow	-877,000	-13,148,000	-61,000	-740,300
Financing Activities
Debt Repayment	95,000	0	-985,000	-1,500
Common Stock Issued/Repurchased	30,876,000	3,009,000	129,379,000	-180,300
Dividends Paid	0	0	0	0
Financing Cash Flow	30,971,000	3,210,000	128,402,000	-1,042,300
Summary
Free Cash Flow	-66,436,000	-42,288,000	-25,874,000	-49,927,100
Net Change in Cash	-36,342,000	-52,035,000	102,528,000	-51,497,701

Cash flow annual history for VistaGen Therapeutics Inc (VTGN).
Cash Flow Statement (Annual)	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Operating Activities
Net Income	-69,685,000	-51,418,000	-29,362,000	-59,247,700	-47,762,400
Depreciation & Amortization	733,000	635,000	568,000	509,800	711,100
Stock Based Compensation	3,997,000	4,315,000	2,182,000	3,336,000	3,480,700
Change in Working Capital	-938,000	4,760,000	793,000	2,028,200	-1,917,900
Operating Cash Flow	-66,436,000	-42,097,000	-25,813,000	-49,715,100	-45,256,500
Investing Activities
Capital Expenditure	-151,000	-191,000	-61,000	-212,000	-200,400
Investments	-151,000	-191,000	-61,000	-212,000	-200,400
Investing Cash Flow	-877,000	-13,148,000	-61,000	-740,300	-200,400
Financing Activities
Debt Repayment	95,000	0	-985,000	-1,500	-3,000
Common Stock Issued/Repurchased	30,876,000	3,009,000	129,379,000	-180,300	949,379,500
Dividends Paid	0	0	0	0	-945,100,000
Financing Cash Flow	30,971,000	3,210,000	128,402,000	-1,042,300	10,483,900
Summary
Free Cash Flow	-66,436,000	-42,288,000	-25,874,000	-49,927,100	-45,456,900
Net Change in Cash	-36,342,000	-52,035,000	102,528,000	-51,497,701	-34,973,000